Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Principal Investigator, Etta Pisano, MD, FACR, will hold informational sessions for prospective domestic (Dec. 3) and international (Dec. 4) sites at the Radiological Society of North America (RSNA) 2019 annual meeting.
Pisano will have plenty to talk about. TMIST now has 81 of the planned 130 sites open and accruing patients for the study. The number of women taking part in the trial has tripled since January.
However, while 40 more potential sites are at various stages of the qualification process, there is still room for more sites and more women to take part.
Benefits of TMIST participation,outlined in this video, have attracted interest from non-academic, community-based women’s health services, large health systems and freestanding radiology facilities alike.
Potential site investigators will have ample opportunity to author papers for major scientific journals regarding this largest breast imaging study in decades.
Trial staff suggest new sites designate specific blocks of research coordinator time to accrue women to the study. Facilities can apply for a $30,000 reimbursement advance to pay for such RA time.
TMIST is the first large randomized controlled trial (RCT) that seeks to identify women in which digital breast tomosynthesis (DBT) may outpace two-dimensional (2D) digital mammography at reducing advanced breast cancer development. TMIST will also create the world’s largest breast cancer biorepository.
Pisano will also hold an informational sessions Oct. 4 at the European Society of Breast Imaging Annual Scientific Meeting in Budapest, Hungary and April 9, 2020 at the Global Breast Cancer Conference 2020 (GBCC 2020) in Seoul, Korea.
Principal Investigator Etta Pisano, MD, FACR, shares the benefits of TMIST participation.
Visit acr.org/TMIST to find out how and why your practice should take part in the largest randomized controlled breast cancer screening trial in decades.
Email TMIST@acr.org with any questions you may have about TMIST.